PanCAN wants every patient facing pancreatic cancer to be empowered to explore clinical trials. They are a critical treatment option in the fight against this tough disease, driving progress for ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...

Together, we can improve pancreatic cancer outcomes. PanCAN supports our patient, caregiver and healthcare professional communities by providing free information and resources. Our services are backed ...

On World Pancreatic Cancer Day, hundreds of patients, caregivers and loved ones tuned in for our special virtual event, “How Early Detection Can Change the Course for Pancreatic Cancer.” Our guests ...

Caregivers are crucial in the pancreatic cancer patient’s journey. We have information and resources to guide you as you care for a loved one facing the disease.

PanCAN’s Precision Promise Clinical Trial Consortium sites were selected through a competitive, peer-review process and include premier cancer treatment institutions across the country.

The U.S. Food and Drug Administration has granted accelerated approval for a new drug targeting a tumor alteration called NRG1 gene fusion found in roughly 3% of patients with pancreatic ...

To speed research advancements and the development of better treatments and early detection tools, the Pancreatic Cancer Action Network (PanCAN) offers grants for basic, translational and clinical ...

A device already approved to treat several other types of cancer has shown positive results for a subset of patients with pancreatic cancer. In a Phase III clinical trial, a therapy known as Tumor ...